Last updated: August 12, 2026
Flurbiprofen sodium is primarily a topical ophthalmic NSAID opportunity. The commercial product is a sterile 0.03% ophthalmic solution used to inhibit intraoperative miosis during cataract surgery and to treat ocular inflammation. The most attractive development paths are preservative-free multidose delivery, improved ocular surface tolerability, unit-dose packaging, and differentiated post-operative combination products. Conventional generic replication has limited strategic value because the reference product is mature and the active ingredient has low concentration, established manufacturing methods, and limited room for price expansion.
What is flurbiprofen sodium used for?
Flurbiprofen sodium is the sodium salt of flurbiprofen, a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin synthesis. In ophthalmology, flurbiprofen sodium ophthalmic solution 0.03% is used before cataract surgery to prevent intraoperative pupillary constriction and after surgery for ocular inflammation.
The principal commercial reference is Ocufen, marketed as flurbiprofen sodium ophthalmic solution 0.03%. The product is administered topically to the eye and is supplied as a sterile aqueous solution. The ophthalmic formulation is distinct from oral flurbiprofen products, including Ansaid, which use flurbiprofen rather than the ophthalmic sodium salt presentation.
Core product profile
| Attribute |
Flurbiprofen sodium ophthalmic solution |
| Active ingredient |
Flurbiprofen sodium |
| Strength |
0.03%, equivalent to 0.03% flurbiprofen |
| Dosage form |
Sterile ophthalmic solution |
| Therapeutic class |
Ophthalmic NSAID |
| Main use |
Prevention of intraoperative miosis and treatment of ocular inflammation |
| Primary route |
Topical ocular |
| Key formulation risks |
Ocular irritation, precipitation, preservative toxicity, sterility, container compatibility |
| Main competitors |
Ketorolac, nepafenac, bromfenac and diclofenac ophthalmic products |
| Regulatory route for copies |
ANDA, subject to applicable FDA requirements |
| Biosimilar exposure |
None; flurbiprofen sodium is a small molecule |
What excipients are used in flurbiprofen sodium ophthalmic products?
The reference and generic flurbiprofen sodium ophthalmic products use a conventional aqueous-buffered formulation. Public product labeling identifies excipient functions that typically include buffering, tonicity adjustment, chelation, viscosity control, pH adjustment and antimicrobial preservation.
Because commercial formulations can differ by manufacturer, the label for the specific product should control any formulation comparison. Typical excipient classes include:
| Excipient class |
Typical examples |
Primary function |
| Buffer |
Boric acid, sodium citrate or citrate salts |
Maintains pH and chemical stability |
| Tonicity agent |
Sodium chloride |
Adjusts osmolality toward ocular tolerance |
| Chelating agent |
Edetate disodium |
Binds trace metals and can improve preservative performance |
| Viscosity modifier |
Polyvinyl alcohol or povidone |
Increases residence time and improves drop feel |
| Preservative |
Benzalkonium chloride in preserved products |
Controls microbial growth after opening |
| pH adjuster |
Sodium hydroxide or hydrochloric acid |
Sets final formulation pH |
| Vehicle |
Purified water |
Aqueous delivery medium |
Why the excipient system matters
The active concentration is low, but the formulation is technically sensitive. Flurbiprofen sodium must remain soluble and chemically stable across the product shelf life. The formulation must also remain comfortable on the ocular surface and avoid damaging the corneal epithelium.
A formulation that uses a strong buffer may improve pH control but increase stinging. A higher-viscosity system can prolong ocular residence time but may cause blurred vision or affect drop formation. Preservatives improve multidose microbiological robustness but can create chronic ocular-surface toxicity concerns.
What is the best excipient strategy for flurbiprofen sodium?
The strongest commercial strategy is a platform approach rather than a single formulation. The first product should establish a low-risk generic or authorized-generic baseline. Follow-on products should use excipient and packaging changes to create differentiated regulatory and commercial positions.
Strategy 1: Conservative generic formulation
A conventional formulation should reproduce the reference product’s critical quality attributes:
- Active concentration and sodium salt form
- pH range
- Osmolality
- Viscosity
- Preservative concentration
- Droplet size and delivered volume
- Appearance and particulate limits
- Sterility and preservative effectiveness
- Container-closure integrity
- Stability under ICH conditions
This approach minimizes development risk and supports an ANDA where the product is therapeutically equivalent to the reference-listed drug. The commercial limitation is substitutability. A standard preserved generic competes mainly on price, supply reliability and wholesaler access.
Strategy 2: Preservative-free unit-dose product
A preservative-free product has the clearest differentiation potential. Unit-dose ampoules or blow-fill-seal containers eliminate benzalkonium chloride exposure and reduce concern about ocular-surface toxicity, particularly in patients with dry eye, repeated dosing or compromised corneal epithelium.
The main technical requirements are:
- Aseptic or terminally sterilized unit-dose manufacturing
- Low extractables and leachables
- Reliable single-use dispensing
- Adequate protection from light and oxygen
- Robust microbial controls
- Acceptable packaging cost
- Low residual volume after dispensing
The commercial tradeoff is higher packaging and manufacturing cost. A preservative-free product is more likely to support premium positioning in ophthalmic surgery centers, hospitals and specialty pharmacies than a conventional bottle.
Strategy 3: Preservative-reduced or alternative-preservative formulation
A reduced-preservative or alternative-preservative product may provide a middle position between a standard multidose bottle and a unit-dose presentation. This route is less differentiated than preservative-free delivery and can create regulatory complexity because the alternative preservative must demonstrate safety, antimicrobial effectiveness and compatibility with the active ingredient.
The strategy is most credible where the delivery system materially reduces contamination risk, such as a sterile multidose bottle with a one-way valve or antimicrobial closure.
Strategy 4: Residence-time enhancement
Polyvinyl alcohol, povidone or another ophthalmically acceptable viscosity modifier can increase ocular residence time and reduce rapid drainage. The formulation must preserve optical clarity and avoid excessive viscosity.
A residence-time formulation could support:
- Fewer daily administrations
- Lower instillation volume
- Reduced runoff
- Improved postoperative adherence
- Differentiation in dry-eye or ocular-surface populations
The evidence burden is higher than for a simple generic because the developer must establish comparable delivery and clinical performance. Any change that materially affects bioavailability, dosing frequency or local tolerability may require more than routine formulation bridging.
Strategy 5: In situ gel or mucoadhesive system
An in situ gelling system can be designed to remain fluid during administration and increase viscosity after contact with the ocular surface. Potential polymers include temperature-responsive, ion-activated or pH-responsive systems.
This approach has technical appeal but weak near-term economics for a mature ophthalmic NSAID. It increases development, manufacturing and regulatory complexity. The product must avoid prolonged blurred vision, excessive residue, difficult drop formation and dose nonuniformity.
The best use case would be a combination product or a formulation aimed at reducing dosing frequency, rather than a premium single-agent generic.
What formulations are protected by patents?
Formulation protection would generally focus on the composition, pH and buffer system, preservative system, viscosity modifier, container-closure system, unit-dose presentation or a defined method of use. The active molecule itself is long established, so commercially relevant protection would more likely arise from:
- Preservative-free formulations.
- Stable high-concentration or low-volume solutions.
- Specific polymer and buffer combinations.
- Multidose containers that limit microbial ingress.
- Ophthalmic suspension or gel systems.
- Combination products containing an NSAID and another postoperative agent.
- Methods that reduce dosing frequency or improve tolerability.
A basic aqueous solution containing familiar ophthalmic excipients is unlikely to provide a strong composition-of-matter position unless it has a narrow, non-obvious combination supported by stability or clinical data.
Patent-strength assessment
| Asset type |
Likely patent strength |
Commercial value |
| Basic aqueous flurbiprofen sodium solution |
Low |
Supports generic equivalence, not durable differentiation |
| Specific buffer and pH window |
Low to moderate |
Useful if stability results are unexpected |
| Preservative-free unit-dose system |
Moderate |
Stronger when linked to packaging and sterility controls |
| Multidose preservative-free dispenser |
Moderate to high |
Potential device and formulation protection |
| In situ gel |
Moderate |
Depends on clinical and performance data |
| Combination product |
Moderate to high |
Can support lifecycle management |
| Manufacturing process |
Moderate |
Relevant where impurity control or yield is difficult |
| Method-of-use claim |
Low to moderate |
Stronger if tied to a defined surgical or high-risk population |
When does flurbiprofen sodium lose exclusivity?
Flurbiprofen sodium ophthalmic products are mature small-molecule products. The primary active-ingredient and conventional formulation patent barriers are generally expired or commercially weak. The relevant competitive question is not loss of basic exclusivity, but whether any later-issued formulation, device or method-of-use patents remain enforceable.
Exclusivity timeline
| Exclusivity category |
Assessment |
| New chemical entity exclusivity |
Expired |
| Small-molecule composition patents |
Expected to be expired for the established active |
| Pediatric exclusivity |
No current commercial significance identified |
| Orphan exclusivity |
Not applicable to the conventional ophthalmic indication |
| Biosimilar exclusivity |
Not applicable |
| Current competitive barrier |
Manufacturing quality, supply, contracting and differentiated delivery |
FDA ANDA applicants can face patent certification requirements under the Hatch-Waxman framework. A Paragraph IV certification is relevant only where an applicant identifies a listed patent as invalid, unenforceable or not infringed. For an old ophthalmic product, the greater risk is usually a later-listed formulation or device patent rather than the original active-ingredient patent. FDA Orange Book listings and the current product-specific patent record should be reviewed before launch planning [1].
What is the Orange Book status of flurbiprofen sodium?
The FDA Orange Book is the controlling source for reference-listed drug status, therapeutic equivalence evaluations and listed patents. Flurbiprofen sodium ophthalmic solution should be assessed by the exact reference-listed product, dosage form, strength and sponsor. Product-specific entries can differ between the reference product and generic products.
For commercial diligence, the relevant checks are:
- Whether Ocufen or another product remains the reference-listed drug.
- Whether the product has a current active FDA approval.
- Whether listed patents remain unexpired.
- Whether any pediatric exclusivity or regulatory exclusivity affects approval timing.
- Whether the proposed generic can rely on an established bioequivalence pathway.
- Whether the product is coded as therapeutically equivalent to the reference.
Because flurbiprofen sodium ophthalmic solution is locally acting, FDA may focus on pharmaceutical equivalence, device performance, quality attributes and comparative clinical considerations rather than a conventional systemic pharmacokinetic study.
Which companies are challenging or competing with flurbiprofen sodium?
The competitive field includes generic ophthalmic manufacturers and branded ophthalmic companies selling alternative NSAIDs. The main therapeutic competitors are:
- Ketorolac tromethamine ophthalmic solution
- Nepafenac ophthalmic suspension
- Bromfenac ophthalmic solution
- Diclofenac sodium ophthalmic solution
These products compete in cataract surgery and postoperative inflammation. Flurbiprofen sodium has a low-cost, established formulation profile but lacks the commercial differentiation of newer products that emphasize reduced dosing frequency, suspension technology or branded surgical-care programs.
Competitive comparison
| Product class |
Main advantage |
Main limitation |
| Flurbiprofen sodium |
Established, low-cost solution |
Older product with limited differentiation |
| Ketorolac |
Broad generic availability and clinical familiarity |
Ocular irritation and frequent dosing concerns |
| Nepafenac |
Prodrug design and postoperative positioning |
Suspension handling and higher cost |
| Bromfenac |
Often positioned for convenient dosing |
Branded or premium pricing in some markets |
| Diclofenac |
Long clinical history |
Tolerability and market substitution pressure |
What commercial opportunities exist for flurbiprofen sodium?
Hospital and ambulatory surgery center supply
A reliable sterile supply is commercially valuable. Cataract surgery is high volume, and supply disruptions can affect surgical protocols. A supplier that offers consistent availability, private-label packaging and institutional contracting can compete even without novel intellectual property.
Preservative-free ophthalmic surgery products
Preservative-free unit-dose products can command a premium where surgeons and facilities prioritize ocular-surface tolerability. The main target is the perioperative market rather than chronic self-administered use.
Combination postoperative regimens
A flurbiprofen sodium combination with an antibiotic, corticosteroid or alternative anti-inflammatory could improve adherence. Combination products face compatibility, stability, dose-ratio and regulatory challenges. They also create stronger differentiation than a single-agent generic.
Emerging-market licensing
Markets with expanding cataract surgery capacity may offer licensing opportunities for local sterile manufacturers. The most viable structure is usually technology transfer plus supply of active pharmaceutical ingredient, primary packaging or validated filling components.
Contract manufacturing and private label
The formulation is suitable for contract manufacturing if the sponsor has validated sterile filling, ophthalmic packaging and preservative-effectiveness capability. Private-label opportunities can target hospital systems, surgical distributors and regional pharmaceutical companies.
What manufacturing and IP barriers affect development?
The active ingredient is not the main barrier. The difficult components are sterile ophthalmic manufacturing and packaging.
Critical manufacturing controls include:
- Control of bioburden before sterilization or aseptic filling
- Uniform dissolution of flurbiprofen sodium
- pH and osmolality control
- Particulate reduction
- Low endotoxin levels
- Fill-volume accuracy
- Container-closure integrity
- Preservative assay and effectiveness
- Extractables and leachables
- In-use stability after opening
A preservative-free product raises the importance of aseptic processing and packaging validation. A multidose product raises the importance of microbial ingress testing and valve performance. A polymer-containing formulation raises risks involving filtration, adsorption, viscosity drift and drop-size variability.
What generic launch risks exist?
The generic launch risk is moderate from a formulation perspective and higher from a commercial perspective.
| Risk |
Impact |
Mitigation |
| Low selling price |
Margin compression |
Secure institutional contracts and efficient packaging |
| Limited differentiation |
Rapid substitution |
Develop preservative-free or device-based variants |
| Sterile manufacturing failure |
Approval delay or supply interruption |
Use an experienced ophthalmic CMO |
| Container compatibility |
Stability failure |
Conduct extractables, leachables and closure studies early |
| Preservative toxicity concerns |
Restricted use in sensitive patients |
Develop unit-dose preservative-free presentation |
| Small market size relative to newer NSAIDs |
Limited return on investment |
Pair with a broader ophthalmic portfolio |
| Later-listed formulation patents |
Paragraph IV or launch delay |
Conduct Orange Book and global patent clearance |
Does flurbiprofen sodium have biosimilar risk?
No. Flurbiprofen sodium is a chemically synthesized small molecule, not a biologic. Biosimilar competition under the Public Health Service Act does not apply. Competition occurs through generic drug applications, abbreviated regulatory pathways, formulation differentiation and branded alternatives.
What is the revenue exposure and market outlook?
Flurbiprofen sodium is unlikely to support blockbuster economics as a standalone generic ophthalmic product. Revenue depends on cataract procedure volumes, reimbursement, generic price erosion, hospital purchasing and the ability to secure reliable supply.
The highest-value opportunity is portfolio-based:
- A standard flurbiprofen sodium ophthalmic generic.
- A preservative-free unit-dose product.
- A broader ophthalmic NSAID or postoperative combination portfolio.
- Institutional and private-label contracts.
- Regional licensing in markets with growing cataract surgery demand.
A standalone conventional bottle is most exposed to price competition. A preservative-free product with validated packaging and a differentiated commercial channel has better pricing potential.
Key Takeaways
- Flurbiprofen sodium is mainly an established ophthalmic NSAID opportunity, not a biologic or biosimilar opportunity.
- The core active-ingredient patent barrier is no longer the primary commercial issue.
- Conventional preserved aqueous solutions are technically straightforward but commercially vulnerable to generic price erosion.
- Preservative-free unit-dose delivery offers the clearest excipient and packaging differentiation.
- Viscosity enhancement and in situ gels are technically possible but add regulatory and manufacturing complexity.
- The strongest patent opportunities involve formulation, container-closure systems, manufacturing controls and combination products.
- Sterile manufacturing, microbial control and packaging compatibility are more important barriers than active pharmaceutical ingredient access.
- Commercial returns improve when flurbiprofen sodium is integrated into a broader ophthalmic surgery portfolio.
Frequently Asked Questions
Can flurbiprofen sodium ophthalmic solution be formulated without benzalkonium chloride?
Yes. A preservative-free product can use unit-dose packaging or a validated multidose system that controls microbial ingress. The formulation must meet sterility, stability, container-closure and in-use performance requirements.
Which excipient is most important for flurbiprofen sodium stability?
The buffer and pH-adjustment system is central because pH affects solubility, chemical stability and ocular tolerability. Edetate disodium can also help control trace-metal effects and support preservative performance.
Is flurbiprofen sodium suitable for an extended-release eye drop?
It is technically suitable for investigation, but an extended-release or in situ gel product requires more development work than a conventional solution. The main risks are blurred vision, dose uniformity, irritation and regulatory bridging.
Can a flurbiprofen sodium formulation patent block a generic applicant?
Yes, if a valid, unexpired formulation, device or method-of-use patent is properly listed and applicable to the proposed product. The original active-ingredient patent is less likely to be the relevant barrier for this mature product.
Is flurbiprofen sodium a good candidate for a fixed-dose ophthalmic combination?
It can be, particularly in postoperative cataract care. The commercial case depends on chemical compatibility, stability, dosing alignment and whether the combination reduces treatment burden compared with separate products.
References
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.). Ocufen: Flurbiprofen sodium ophthalmic solution 0.03% prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.
-
International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.
-
United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.
